Trailing-twelve-month (TTM) revenue is $66.40 Billion with a year-over-year growth of +4.24%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $17,183,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $16,324,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-03-31 | $16,286,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-04 |
| Q2 FY2026Period ended 2026-06-30 | $16,607,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-07 |
| TTM revenue | $66,400,000,000 |
Current P/S: $358,197,991,585 market capitalization ÷ $66,400,000,000 TTM revenue = 5.39x.
Market capitalization source: FMP quote. Quote observed 2026-09-10T17:20:40.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $16.61B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-10T17:20:40.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-30 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Animal Health segment | $4.7B | $5.6B | $5.5B | $5.6B | $5.9B | $6.4B |
| Other Segments | $23M | $382M | $1.7B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-30 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Animal Health segment | N/A | N/A | N/A | $5.6B | N/A | N/A |
| Asia Pacific | $2.9B | $2.4B |
$66.40B
$66.40 Billion
+4.24%
vs. $63.70B a year ago (TTM)
+7.87%
5 Year compound annual growth rate
1 Year
+4.24%
3 Year
+4.42%
5 Year
+7.87%
10 Year
+5.35%
15 Year
+2.34%
20 Year
+5.59%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $64.93B | +$758.00M | +1.18% |
| 2024 | $64.17B | +$4.05B | +6.74% |
| 2023 | $60.12B | +$832.00M | +1.40% |
| 2022 | $59.28B | +$10.58B | +21.72% |
| 2021 | $48.70B | +$7.19B | +17.31% |
| 2020 |
TTM Growth
+4.24%
3-Year CAGR
+4.42%
5-Year CAGR
+7.87%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-10T17:20:40.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $891M |
| $515M |
| Pharmaceutical segment | $43.0B | $42.8B | $52.0B | $53.6B | $57.4B | $58.1B |
|---|
| N/A |
| $3.1B |
| $3.0B |
| CHINA | $3.6B | $4.4B | $5.2B | N/A | $5.5B | $1.9B |
|---|
| EMEA | $13.6B | $13.3B | $14.5B | N/A | $14.0B | $14.6B |
|---|
| International | $1.2B | $1.2B | $2.6B | N/A | $2.6B | $2.9B |
|---|
| JAPAN | $3.4B | $2.7B | $3.6B | N/A | $3.3B | $2.7B |
|---|
| Latin America | $2.3B | $2.2B | $2.6B | N/A | $3.5B | $3.4B |
|---|
| Other Segments | N/A | N/A | N/A | $907M | N/A | N/A |
|---|
| Pharmaceutical segment | N/A | N/A | N/A | $53.6B | N/A | N/A |
|---|
| UNITED STATES | $21.0B | $22.4B | $27.2B | N/A | $32.3B | $36.5B |
|---|
| $41.52B |
| +$2.40B |
| +6.13% |
| 2019 | $39.12B | ($3.17B) | (7.50%) |
| 2018 | $42.29B | +$2.17B | +5.41% |
| 2017 | $40.12B | +$315.00M | +0.79% |
| 2016 | $39.81B | +$309.00M | +0.78% |
